EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

  1. Rosenberg, J.E.
  2. Powles, T.
  3. Sonpavde, G.P.
  4. Loriot, Y.
  5. Duran, I.
  6. Lee, J.-L.
  7. Matsubara, N.
  8. Vulsteke, C.
  9. Castellano, D.
  10. Mamtani, R.
  11. Wu, C.
  12. Matsangou, M.
  13. Campbell, M.
  14. Petrylak, D.P.
Aldizkaria:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Argitalpen urtea: 2023

Mota: Artikulua

DOI: 10.1016/J.ANNONC.2023.08.016 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus